Poly (ADP-ribosylation) of HMGB1 Facilitates Its Acetylation and Promotes HMGB1 Translocation-associated Chemotherapy-induced Autophagy in Leukaemia Cells
Overview
Authors
Affiliations
Acute lymphoblastic leukaemia (ALL) is one of the most common and curable types of cancer in paediatric patients. However, chemotherapeutic resistance is a difficult but common obstacle when treating leukaemia in the clinical setting. Studies have demonstrated that drug resistance is partly attributable to autophagy induced by multiple chemotherapeutic agents. As an evolutionarily conserved non-histone chromatin-binding protein, high mobility group box protein 1 (HMGB1) is considered to be an important factor in autophagy, and regulates autophagy at multiple levels via different subcellular localisations. In the present study, it was revealed that chemotherapeutic drugs induced autophagy in leukaemia cells and that translocation of HMGB1 from the nucleus to the cytoplasm is an important molecular event in this process. It was further demonstrated that poly (ADP-ribosylation) of HMGB1 facilitates its acetylation, thereby inducing HMGB1 translocation and ultimately promoting chemotherapy-induced autophagy in leukaemic cells. Targeted HMGB1 translocation may overcome chemotherapy-induced autophagy in leukaemia.
Gillespie K, Pirnie R, Mesaros C, Blair I Biomolecules. 2023; 13(9).
PMID: 37759736 PMC: 10526420. DOI: 10.3390/biom13091335.
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma.
Bashiri H, Tabatabaeian H Int J Mol Sci. 2023; 24(7).
PMID: 37046991 PMC: 10094562. DOI: 10.3390/ijms24076019.
Sun Y, Wang Q, Wang M, Sun F, Qiao P, Jiang A Cell Mol Life Sci. 2022; 80(1):13.
PMID: 36536161 PMC: 11073454. DOI: 10.1007/s00018-022-04637-z.
The mechanism of HMGB1 secretion and release.
Chen R, Kang R, Tang D Exp Mol Med. 2022; 54(2):91-102.
PMID: 35217834 PMC: 8894452. DOI: 10.1038/s12276-022-00736-w.
Lysine Acetylation, Cancer Hallmarks and Emerging Onco-Therapeutic Opportunities.
Hu M, He F, Thompson E, Ostrikov K, Dai X Cancers (Basel). 2022; 14(2).
PMID: 35053509 PMC: 8773583. DOI: 10.3390/cancers14020346.